Avencell Therapeutics
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
500 Forge Rd, Watertown, Massachusetts, ...Phone Number
(617) 941-7468Website
www.avencell.comRevenue
$7.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Avencell Therapeutics
AvenCell Therapeutics, Inc. was recently launched by Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics and incorporated the clinical-stage biopharmaceutical company GEMoaB GmbH, now named AvenCell Europe GmbH. With $250 million in committed capital from Blackstone as its sole founding investor, AvenCell brings together switchable universal T cell technology developed by the former Cellex subsidiary GEMoaB GmbH, with a license to Intellias proprietary CRISPR/Cas9-based allogeneic platform to create a pipeline of autologous and allogeneic universal reprogrammable T cell products, focused initially on hard-to-treat cancers. AvenCells mission is to overcome the limitations of current-generation CAR-T cell therapies with an improved therapeutic window and substantially expand the types of cancer, including solid tumors, treatable with adoptive cell therapy.Explore more
Avencell Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Avencell Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check out if Avencell Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Avencell Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Avencell Therapeutics launches new products
Avencell Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Avencell Therapeutics
Earning: See what the market has to say on Avencell Therapeutics recently announced quarterly report
Click to see if Avencell Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Avencell Therapeutics has new funding data
Recommended Actions
Reach out to Masked Content who joined Avencell Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Avencell Therapeutics
Compare insights from companies similar to Avencell Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Avencell Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Avencell Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Avencell Therapeutics.
Avencell Therapeutics financials insights
Gather financial insights about Avencell Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Series B
$112M
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Product Development, Product Management, Governmental Affairs & Regulation, Medical Research, Pharmaceuticals, Clinical Operations, Regulations
Left Company
Executive Move
Executive Moves, Left Company
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Avencell Therapeutics News & Media
AvenCell Therapeutics Announces First Patient Dosed in Phase I QUADvance Study with AVC-203, a Novel Allogeneic CD19/CD20 Dual-Targeting CAR-T Investigational Therapy for the Treatment of Relapsed/Refractory B-Cell Malignancies
AVC-203 is the world's first CRISPR-engineered allogeneic dual-targeting CD19/CD20 switchable CAR-T cell therapy to enter clinical testing WATERTOWN, Mass., April 2, 2026 /PRNewswire/ -- AvenCell Therapeutics, Inc., a leading clinical-stage cell therapy company focused on advancing both...AvenCell Therapeutics Announces IND Clearance and EMA Approval of Clinical Trial Application (CTA) for the QUADvance Study, a Phase I/II trial evaluating AVC-203, a Novel Allogeneic CD19/CD20 CAR-T Investigational Therapy for the Treatment of Relapsed/Refractory B-cell malignancies
CAMBRIDGE, Mass., Dec. 4, 2025 /PRNewswire/ -- AvenCell Therapeutics, Inc., a leading clinical-stage cell therapy company focused on advancing both switchable and allogeneic CAR-T cell therapies, today announced that the FDA and the European Medicines Agency (EMA) have cleared the...AvenCell Awarded Up to $40 Million AMED Grant to Advance Allogeneic CAR-T Program
TOKYO, June 30, 2025 /PRNewswire/ -- AvenCell Japan, a wholly owned subsidiary of AvenCell Therapeutics, a private, clinical-stage biotechnology company developing best-in-class CAR-T therapies for hematologic cancers and autoimmune diseases, today announced it has been awarded a grant of...AvenCell: Clinical-Stage Cell Therapy Company Raises $112 Million (Series B) - Pulse 2.0
AvenCell Therapeutics - a leading clinical-stage cell therapy company focused on advancing both autologous and allogeneic switchable CAR-T cell therapies - announced that it has raised $112 million in Series B funding. Global life sciences investor Novo Holdings led the funding.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Avencell Therapeutics
Sign Up For FreeTo access detailed company insights
AvenCell Therapeutics, Inc. was recently launched by Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics and incorporated the clinical-stage biopharmaceutical company GEMoaB GmbH, now named AvenCell Europe GmbH. With $250 million in committed capital from Blackstone as its sole founding investor, AvenCell brings together... Read More
